EuroPCR 2019 | BASKET-SMALL 2: balones farmacológicos vs DES en vasos pequeños

EuroPCR 2019 | BASKET-SMALL 2: Drug-Coated Balloons vs. DES in Small Vessels

This angiographic substudy supports the safety of drug-coated balloons in small vessels. Despite better angiographic outcomes, there were eight cases of stent thrombosis among drug-eluting stent (DES) patients, while there was none with drug-coated balloons. In patients with small vessels, using a drug-coated balloon appears safe and comparable to DES, with favorable angiographic outcomes at<a href="https://solaci.org/en/2019/05/27/europcr-2019-basket-small-2-drug-coated-balloons-vs-des-in-small-vessels/" title="Read more" >...</a>

REVELATION: Balones liberadores de droga en infartos con supradesnivel del segmento ST

EuroPCR 2019 | REVELATION: Drug Coated Balloons in ST Elevation MI

Drug coated balloons in the context of ST elevation acute myocardial infarction seem safe and feasible under certain circumstances. This single center study is the kickoff to keep studying the possibility of “leaving nothing behind” after primary PCI. This small randomized study revives drug coated balloons to be used particularly instead of stents in young<a href="https://solaci.org/en/2019/05/24/europcr-2019-revelation-drug-coated-balloons-in-st-elevation-mi/" title="Read more" >...</a>

BIO-RESORT y registro SCAAR: Struts ultrafinos también en vasos pequeños

EuroPCR 2019 | BIO-RESORT and SCAAR Registry: Ultrathin Struts Also in Small Vessels pequeños

Data from randomized studies are also supported by the SCAAR registry, in which ultrathin-strut stents show real-world advantages. Patients with small vessels who received ultrathin-strut stents are less likely to undergo revascularization at 3 years than those who received first-generation thin-strut devices, according to the BIO-RESORT trial, presented during the first day of the annual<a href="https://solaci.org/en/2019/05/23/europcr-2019-bio-resort-and-scaar-registry-ultrathin-struts-also-in-small-vessels-pequenos/" title="Read more" >...</a>

EuroPCR 2019 | Global Leaders: La monoterapia con ticagrelor a largo plazo podría tener un lugar en angioplastias complejas.

EuroPCR 2019 | Global Leaders: Ticagrelor Monotherapy at Long Term Could Have a Role in Complex PCI

This post hoc analysis of what had been a trial with negative outcomes should be considered only as a hypothesis generator. Patients receiving complex PCI treated with ticagrelor monotherapy after one-month dual antiaggregation therapy (DAPT) showed better results at 2 years when compared against patients receiving a conventional DAPT scheme. In the global analysis, this<a href="https://solaci.org/en/2019/05/23/europcr-2019-global-leaders-ticagrelor-monotherapy-at-long-term-could-have-a-role-in-complex-pci/" title="Read more" >...</a>

angioplastia a tronco de coronaria izquierda vs cirugia

Surprising EXCEL Outcomes in Diabetics with Main Left Stenosis

This study especially designed to compare PCI vs. CABG in patients with left main coronary artery disease and low to intermediate Syntax score showed that 30-day and 3 -year outcomes of PCI with everolimus eluting stents vs CABG were consistent both in diabetic and non-diabetic patients. The randomized EXCEL trial (Evaluation of XIENCE versus Coronary<a href="https://solaci.org/en/2019/05/09/surprising-excel-outcomes-in-diabetics-with-main-left-stenosis/" title="Read more" >...</a>

The Most Read Scientific Articles in Interventional Cardiology

1- Long-Term Foramen Ovale Closure after Cryptogenic Stroke Patent foramen ovale closure is the standard treatment for cryptogenic stroke patients. However, there are is little information on its long-term evolution. Read more   2- Descending Thoracic Aortic Aneurysms: Is There a New Plan A? The last available evidence suggests that open surgery should be the<a href="https://solaci.org/en/2019/05/03/the-most-read-scientific-articles-in-interventional-cardiology/" title="Read more" >...</a>

La meseta por la que transcurre la cirugía desde hace varios años

Outcomes of MAIN-COMPARE: A 10-Year Follow-Up for a Historical Rivalry

Angioplasty and myocardial revascularization surgery have competed over the left main coronary artery for a long time. There may be many points of view involved in the interpretation of trial outcomes. While surgeons consider the left main coronary artery to be suitable for surgery (except when faced with surgical contraindications), interventional cardiologists see the left<a href="https://solaci.org/en/2019/04/30/outcomes-of-main-compare-a-10-year-follow-up-for-a-historical-rivalry/" title="Read more" >...</a>

The Most Read Articles of March in Interventional Cardiology

1- What to Do with Blood Pressure Levels Between 130/80 and 139/89 mmHg The decision to be made with a treatment-free patient with systolic blood pressure over 160 mmHg or diastolic blood pressure over 100 mmHg is an easy one. All guidelines agree: treatment should be started immediately alongside lifestyle changes. Read more   2-<a href="https://solaci.org/en/2019/04/22/the-most-read-articles-of-march-in-interventional-cardiology/" title="Read more" >...</a>

Subclavian and Axillary Access for TAVR: a Valid Alternative

Courtesy of Dr. Carlos Fava. The femoral approach is preferred when it comes to TAVR, but sometimes it is not viable. This is when other access sites come into play, such as the trans-subclavian/axillary (TS/TAx), the apical, transcaval, transcarotid (TC) or transaortic. At present, few studies have looked into this matter, which is why it<a href="https://solaci.org/en/2019/04/11/subclavian-and-axillary-access-for-tavr-a-valid-alternative/" title="Read more" >...</a>

La complejidad de la angioplastia puede definir el tiempo de doble antiagregación

Balancing Bleeding Risk vs. Thrombotic Risk to Define Dual Antiplatelet Therapy Duration

Patients who undergo complex angioplasty are at higher ischemic risk, but only benefit from extended dual antiplatelet therapy if there are no factors for high bleeding risk. These data suggest that the bleeding risk must weigh more than the ischemic risk on the determination of dual antiplatelet therapy duration. Complex angioplasty is associated with higher<a href="https://solaci.org/en/2019/04/05/balancing-bleeding-risk-vs-thrombotic-risk-to-define-dual-antiplatelet-therapy-duration/" title="Read more" >...</a>